

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**百信集团**  
PASHUN GROUP

**Pa Shun Pharmaceutical International Holdings Limited**

**百信藥業國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 574)**

## **VOLUNTARY ANNOUNCEMENT ISSUE OF CORPORATE BONDS**

This is a voluntary announcement made by Pa Shun Pharmaceutical International Holdings Limited (the “**Company**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that during the period from 22 November 2016 to the date of this announcement, the Company entered into separate subscription agreements (the “**Subscription Agreements**”) with 14 independent private investors (the “**Subscribers**”), pursuant to which the Subscribers agreed to subscribe for and the Company agreed to issue corporate bonds (the “**Corporate Bonds**”) in the aggregate principal amount of HK\$36,000,000 at par value, bearing coupon rate of 7% per annum and with maturity from 3 to 7.5 years (the “**Subscriptions**”). As at the date of this announcement, the Subscriptions were all completed.

To the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, each of the Subscribers is a third party independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited). The Board is of the view that the terms of each of the Subscription Agreements and the transactions contemplated thereunder are on normal commercial terms, fair and reasonable, and are in the interest of the Company and its shareholders as a whole. The net proceeds from the Subscriptions will be utilised as general working capital of the Company and its subsidiaries (the “**Group**”).

It is the plan of the Group to further issue corporate bonds under substantially the same terms as the Corporate Bonds to potential investors (if any) in the aggregate principal amount of up to HK\$24,000,000 at par value within 6 months from the date of this announcement.

By order of the Board

**Pa Shun Pharmaceutical International Holdings Limited**

**Mr. Chen Yenfei**

*Chairman*

Hong Kong, 24 January 2017

*As at the date of this announcement, the executive directors of the Company are Mr. Chen Yenfei, Mr. Shen Shun, Mr. Zhou Jian; the non-executive directors of the Company are Mr. Li Ho Tan, Mr. Masahiro Honna and Mr. Zhang Xiongfeng; and the independent non-executive directors of the Company are Mr. Liu Liangzhong, Mr. Wong Tak Shing and Mr. Min Feng.*